-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
-
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
-
ADC Therapeutics to Present at November Investor Conferences
-
ADC Therapeutics raises $60 million in private equity financing
-
ADC Therapeutics Announces $60 Million Private Placement
-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025
-
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
-
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
-
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
-
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan
-
ADC Therapeutics SA (ADCT) Announces Updated Data from ZYNLONTA Investigator-Initiated Trial R/R Marginal Zone Lymphoma
-
ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
-
ADC Therapeutics SA (ADCT) Prices $100M Share Offering at $3.53/sh
-
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
-
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
-
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
-
David Moenning's Daily State of the Markets: 5/8
-
Morning Movers 12/10: Rio Tinto (RTP) Up On Capital Plans/Job Cuts; Electronic Arts (ERTS) Sinks On Guidance

